Yvon Rabemampianina

TL;DR: An initiative between the European Federation of Pharmaceutical Industries Associations and the European Centre for the Validation of Alternative Methods to provide the researcher in the safety evaluation laboratory with an up‐to‐date, easy‐to-use set of data sheets to aid in the study design process.

TL;DR: This review of the dog, the primary nonrodent species used in toxicology, and its use in the safety evaluation of pharmaceuticals, provides data on the number used in particular projects in an effort to establish a baseline from which some minimization can be measured.

TL;DR: The implementation of such an optimised design is believed to result in a reduction in the overall numbers of animals used for safety testing, without jeopardising the scientific rationale and usefulness of the studies for informing the conduct of later regulatory studies.

TL;DR: There is no universal formula for QTc calculation in dogs, and each laboratory should have its own formula, based on the analysis of data obtained from the strain used in its own experimental conditions.

TL;DR: In this paper, the authors proposed a best practice guide on aspects of study design, including group sizes, use of control animals, single sex studies and design of maximum tolerated dose (MTD) studies.